Table 1.
Material | Supplement | Modulus [kPa] b) | Animal model | Significant finding(s) |
---|---|---|---|---|
| ||||
Fibrin | Fibronectin | - | Rat SCI | Fibronectin supplement better supports axon ingrowth compared to fibrin or fibronectin hydrogels alone[89] |
Fibrin a) | chABC | - | Rat SCI | Fibrin prolongs chABC release which reduces glycosaminoglycan content compared to chABC injections[96] |
Fibrin | - | - | Rat SCI | MSC-loaded hydrogel improved neurite extension and functional recovery[88] |
Fibrin | chABC-loaded lipid microtubes and NEP1–40 loaded PLGA microspheres | - | Rat SCI | Drug-loaded composite improved axon growth, reduced astrocyte scarring, and reduced the presence of CSPGs around the injury site. |
Fibrin a) | Laminin, VEGF, and NGF | - | Rat cortical implant Rat hemi-Parkinson |
Protein-immobilized hydrogels recruit endogenous neuronal cells and enhance neurite ingrowth Protein-immobilized hydrogels correct parkinsonian behavior[95] |
AFG | - | 1.6 | Rat SCI | AFGs promote neuronal cell migration and guide axonal invasion[84] |
AFG | - | 1.6 | Rat PNI | AFGs advance injury gap bridging and improve functional recovery[86] |
Fibrin a) | T1, HYD1, or A5G81 synthetic ligands | 0.25 – 0.32 | Rat SCI | HYD1-immobilization boosts growth cone formation and functional recovery [90] |
Fibrin | Tacrolimus-loaded PLGA microparticles | - | Rat PNI | Slowed drug release from microparticles improves neurogenesis[99] |
AFG | - | 1.6 | Rat SCI | MSC-loaded AFGs produce nerve bundles that cross the injury site and improve functional recovery[85] |
inclusion of aprotinin, an enzyme inhibitor that reduces fibrin degradation
storage (elastic) modulus.